Testing effectiveness (Phase 2)Not Yet RecruitingNCT07612007
What this trial is testing
HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization
Who this might be right for
Metastatic Colorectal CarcinomaMetastatic Malignant Neoplasm in the LiverResectable Colorectal Carcinoma+1 more
Mayo Clinic 80